Mayne Pharma Group Ltd (ASX: MYX) Share Price and News

Price

 

Movement

   

  (20 mins delayed)

52 Week Range

  -  

 
1 Year Return

 

Mayne Pharma Group Ltd Chart and Price Data

Fundamentals Data provided by Morningstar.

Data provided by Morningstar.
Market Cap $502.98 million
P/E Ratio N/A
Dividend Yield N/A
Shares Outstanding 1.76 billion
Earnings per share -0.048
Dividend per share N/A
Year To Date Return -5.08%
Earnings Yield N/A
Franking N/A
Share Price

Day Change

52 Week Range

-

Yesterday's Close

Today's Open

Days Range

-

Volume

Avg. Volume (1 month)

Turnover

as at 24 Feb 3:44pm

Should you invest $1,000 in right now?

Before you consider , you’ll want to hear this.

Motley Fool Investing expert Scott Phillips just revealed what he believes are the 5 best stocks for investors to buy right now… and wasn’t one of them.

The online investing service he’s run for nearly a decade, Motley Fool Share Advisor, has provided thousands of paying members with stock picks that have doubled, tripled or even more.* And right now, Scott thinks there are 5 stocks that are better buys.

*Returns as of August 16th 2021

Mayne Pharma Group Ltd (ASX: MYX)
Latest News

a medical researcher rests his forehead on his fist with a dejected look on his face while sitting behind a scientific microscope with another researcher's hand on his shoulder as if giving comfort.
Earnings Results

Mayne Pharma (ASX:MYX) share price slides on 38% EBITDA slump

We take a look at the pharmaceutical company's half-year results.

Read more »

ASX shares downgrade A young woman with tattoos puts both thumbs down and scrunches her face with the bad news.
Share Fallers

Why Bapcor, Mayne Pharma, Race Oncology, and TechnologyOne shares are sinking

These ASX shares are falling on Wednesday...

Read more »

Thumbs down Facebook icon over dark screen
Share Fallers

Why Integral Diagnostics, Mayne Pharma, NEXTDC, & Wesfarmers are dropping

These ASX shares are ending the week in the red...

Read more »

white arrow pointing down
Share Fallers

Mayne Pharma (ASX:MYX) share price crashes 10% on $208.4m loss in FY21

It has been another tough year for Mayne Pharma...

Read more »

white arrow dropping down representing the 10 most shorted shares on the ASX
Share Market News

ASX 200 drops, Afterpay jumps again, Credit Corp rises

The ASX 200 fell, however the Afterpay share price jumped again.

Read more »

share price plummeting down
Share Fallers

Why Bubs, Mayne Pharma, Paradigm, & PointsBet shares are tumbling lower

These ASX shares are not having a great day...

Read more »

a legal gavel rests near a bottle of pharmaceutical pills with the contents spilling onto the desk.
Share Fallers

Mayne Pharma (ASX:MYX) share price drops on class action

The pharmaceutical company is the subject of legal proceedings.

Read more »

Bag of white pills spilled onto a blue surface
Share Fallers

Mayne Pharma (ASX:MYX) share price lower despite positive updates

This pharmaceutical company has made a couple of announcements today...

Read more »

MYX ASX Announcements

An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.

DateAnnouncementPrice Sensitive?TimeNo. of PagesFile Size
YesNo

About Mayne Pharma Group Ltd

Mayne Pharma Group Ltd (ASX: MYX) is a specialty pharmaceutical company that applies its drug delivery expertise to commercialise branded and generic pharmaceuticals. The company also provides contract development and manufacturing services to more than 100 clients worldwide.

Mayne Pharma is technology driven with a significant product portfolio and pipeline, and global reach through distribution partners in Australia, North America, Europe and Asia. The company has product development and manufacturing facilities in Salisbury, Australia and Greenville, North Carolina, USA with expertise in formulating complex oral and topical dose forms. The business is supported by more than 900 staff globally with more than 200 scientists employed.

The Salisbury facility is capable of developing products from formulation and clinical trial stages to validation and registration, right through to commercial scale manufacture of packaged goods.

MYX Share Price History Data provided by Morningstar.

Data provided by Morningstar.
Date Close Change % Change Volume Open High Low
16 May 2022 $0.29 $0.00 0.00% 1,388,821 $0.28 $0.29 $0.28
13 May 2022 $0.28 $0.01 3.70% 3,247,219 $0.27 $0.28 $0.27
12 May 2022 $0.27 $-0.01 -3.64% 4,885,058 $0.27 $0.28 $0.26
11 May 2022 $0.28 $0.01 3.77% 2,398,788 $0.27 $0.28 $0.26
10 May 2022 $0.27 $-0.02 -7.02% 4,933,500 $0.28 $0.29 $0.26
09 May 2022 $0.29 $0.00 0.00% 2,283,755 $0.28 $0.29 $0.28
06 May 2022 $0.29 $0.00 0.00% 2,826,428 $0.28 $0.29 $0.27
05 May 2022 $0.29 $0.00 0.00% 1,357,220 $0.29 $0.30 $0.28
04 May 2022 $0.29 $-0.01 -3.45% 2,785,345 $0.29 $0.29 $0.28
03 May 2022 $0.29 $0.01 3.57% 1,611,063 $0.28 $0.29 $0.28
02 May 2022 $0.28 $0.00 0.00% 1,962,899 $0.28 $0.29 $0.28
29 Apr 2022 $0.29 $0.01 3.64% 2,478,441 $0.28 $0.29 $0.27
28 Apr 2022 $0.28 $0.00 0.00% 3,036,733 $0.27 $0.28 $0.27
27 Apr 2022 $0.28 $0.00 0.00% 1,627,404 $0.27 $0.28 $0.27
26 Apr 2022 $0.28 $-0.01 -3.51% 3,663,104 $0.28 $0.29 $0.27
22 Apr 2022 $0.29 $-0.02 -6.56% 8,488,477 $0.30 $0.30 $0.29
21 Apr 2022 $0.31 $0.01 3.33% 9,070,350 $0.30 $0.31 $0.29
20 Apr 2022 $0.30 $0.01 3.45% 5,953,698 $0.30 $0.30 $0.29

Director Transactions Data provided by Morningstar.

Data provided by Morningstar.
Date Director Type Amount Value Notes
03 Dec 2021 Scott Richards Issued 6 $1,636,363
Issue of securities. 9,741,903 - Performance Rights
01 Sep 2021 Frank Condella Buy 412 $136,679
On-market trade.

Directors & Management Data provided by Morningstar.

Data provided by Morningstar.
Name Title Start Date Profile
Mr Frank Condella Non-Executive DirectorNon-Executive Chairman May 2018
Mr Condella has over 30 years of experience in senior executive roles in the global pharmaceutical industry. His operating experience includes CEO of Juniper Pharmaceuticals, a CDMO and specialty pharmaceutical company, which was subsequently sold to Catalent. Previously he served as CEO of Skyepharma Plc, President of European operations at IVAX (Teva), CEO of Faulding Pharmaceuticals, Vice President of Specialty Care Products at Roche and Vice President and General Manager of the Lederle Standard Products (Pfizer). Mr Condella's previous board experience includes Chairman of Skyepharma Plc until it merged with Vectura, Vice Chairman of Vectura Plc, Independent Director of Prosonix ltd, Independent Director of Fulcrum Pharma plc, and Chairman of the PKD Foundation. He currently also serves as an Independent Director for Fertin Pharma A/S (Denmark) and Palladio Biosciences Inc (US). Mr Condella is a member of Mayne Pharma's Science, Technology and Medical Committee.
Mr Ian Frank Scholes Non-Executive DirectorNon-Executive Deputy Chairman Oct 2007
Mr Scholes has e financial and corporate advisory experience, both in Australia and internationally. Mr Scholes held a number of senior roles within Merrill Lynch Australia, including Managing Director and Vice Chairman of Investment Banking. Previously Mr Scholes held the position of Executive General Manager at National Australia Bank Limited, running the corporate and institutional banking division. Mr Scholes is currently a Partner and CEO of Chord Capital Pty Ltd. Mr Scholes has previously held positions on the Board of St Vincent's Health as Chairman of the St Vincent's Foundation and was a former Director of SDI Limited. Mr Scholes is also Chairman of Mayne Pharma's Risk Committee and a member of the People Committee.
Mr Scott Anthony Richards Chief Executive OfficerManaging Director Feb 2012
Mr Richards has more than 30 years experience in the pharmaceutical industry and has worked in Europe, the US and Asia. Previously, Mr Richards has had spend 10 years in Europe serving leadership roles including President, Europe Middle East and Africa. He also served on the Group Management Board of Actavis for 4 years where he was in charge for the firm's injectable/hospital business operations. Prior to working in Europe, Mr Richards had spend 14 years with FH Faulding and Co., in roles including Faulding Pharmaceuticals Asia Pacific operations together with spending 5 years with Faulding in the US business development and portfolio management operations. Mr Richards experience spans sales and marketing, medical affairs, supply chain, business development, mergers and acquisitions, finance, intellectual property and manufacturing.
Professor Bruce Gregory Robinson Non-Executive Director Aug 2014
Professor Robinson is former Dean of University of Sydney's Sydney Medical School. He has been the head of the Cancer Genetics Unit at the Kolling Institute of Medical Research, Royal North Shore Hospital since 1989. Since 2001, he has been Chairman of Hoc Mai Foundation, a program in medical and health education and exchange with Vietnam. He is a Non-Executive Director of Cochlear Limited, Lorica and QBiotics Group Limited. He is a Board Member of the Woolcock Institute, is Chair of National Health and Medical Research Council and Chair of the Medical Benefits Review Taskforce. Prof Robinson is Chairman of the Science, Technology and Medical Committee.
Mr Patrick J Blake Non-Executive Director Jun 2018
Mr Blake has over 30 years of healthcare industry experience including more than 20 years at McKesson Corporation one of the healthcare services and information technology companies globally, and more than 10 years at Baxter Healthcare Corporation. Recently, he was Executive Vice President of McKesson Corporation and Group President of McKesson Technology Solutions which services the health IT needs of hospitals and health systems, payers, physicians, homecare agencies, retail pharmacies and manufacturers, a position he held from 2009 until 2017. Previously, he was President of McKesson Specialty Health, a business focussed on the US specialty/biotech sector which was McKesson's business for three years during his leadership. He was also President of Customer Operations for McKesson Pharmaceutical (US) from 2000 to 2006, led sales and operations for the wholesale distribution of branded and generic pharmaceuticals and other related products. Mr Blake is a Member of the Risk and People Committee.
Ms Ann Custin Non-Executive Director Mar 2022
Ms Custin has almost 40 years of experience in the healthcare sector. She is an experienced executive with healthcare commercial experience across the US, Europe and Asia. She also has experience in strategy, financial planning and reporting, portfolio management, sales operations, manufacturing, risk management, business and corporate development. Most recently, Ms Custin was Board Director and CFO of Siemens Medical Solutions (now Siemens Healthineers), a medical technology company. Previously, she was Chief Operating and Financial Officer of Scient'x Group and President and CEO of USA Draeger Medical Systems. Ms Custin is currently a director of two women's health focused companies - ASX-listed Volpara Health and NASDAQ-listed Establishment Labs. She will also join Mayne Pharma's Risk Committee effective 23/03/2022.
Dr Carolyn Myers Non-Executive Director Oct 2021
Dr Myers is an experienced pharmaceutical executive having held senior leadership roles at Allergan, Forest Labs, Mylan (now Viatris) and Pharmacia (now Pfizer). She has 30 years of experience in the pharmaceutical industry and is currently CEO of FendX technologies, a medical technology company formed to develop and commercialise products using a unique pathogenrepelling technology. She is also Principal of BioEnsemble, providing consulting services to small and mid-size pharma, biotech and medical technology companies. Previously, she was Vice President of Global Alliance Management and International Business Development at Allergan, Vice President of Marketing at Forest Laboratories, President of Dey Laboratories and President of Mylan Technologies. Dr Myers is a Steering Committee member of Mid Atlantic Bio Angels, a committee member of Golden Seeds and an independent board member of Hyloris Pharmaceuticals.
Dr Kathryn MacFarlane Non-Executive Director Feb 2022
Dr MacFarlane has more than 30 years of experience in the pharmaceutical industry. She also has experience in launch planning, sales and marketing, product reimbursement, strategy, business development and clinical R&D. Her experience spans multiple therapeutic areas including women's health and dermatology. She is currently Founder and Managing Partner of SmartPharma LLC, offering commercial and strategic consulting services to pharmaceutical companies. Previously, she was Chief Commercial Officer at Agile Therapeutics, Vice President Women's Health Care Marketing, Sales and New Product Planning at Warner Chilcott and Senior Director of Marketing at ParkeDavis (now Pfizer). Dr MacFarlane is a Director of RespireRx Pharmaceuticals, Inc., a member of the Purdue University School of Pharmacy Dean's Advisory Council and a Founding Member and Advisor to IPhO. She also serves on the Board of Directors for INMED Partnerships for Children, an NGO.
Ms Laura Loftus Company Secretary Mar 2020
-
Laura Loftus Company Secretary
-

Top Shareholders Data provided by Morningstar.

Data provided by Morningstar.
Name Shares Capital
HSBC Custody Nominees (Australia) Limited 215,194,570 12.20%
Citicorp Nominees Pty Limited 182,907,070 10.40%
Estetra Srl 168,872,626 9.60%
Mr Bruce Mathieson And Related Entities 105,577,583 6.00%
Solium Nominees (Australia) Pty Ltd (Bare Allocated A/C) 101,323,754 5.70%
J P Morgan Nominees Australia Pty Limited 95,117,187 5.40%
BNP Paribas Nominees Pty Ltd (Agency Lending Drp A/C) 31,095,949 1.80%
BNP Paribas Noms Pty Ltd (Drp) 18,784,099 1.10%
Solium Nominees (Aus) Pty Ltd (Unallocated A/C) 17,554,187 1.00%
Ivl Group Pty Ltd 16,000,000 0.90%
Citicorp Nominees Pty Limited (Colonial First State Inv A/C) 14,275,000 0.80%
Y S Chains Pty Ltd 13,100,000 0.70%
Mr Roger Corbett And Related Entities 10,440,569 0.60%
Vivnat (Curtin) Pty Ltd 10,000,000 0.60%
Wal Assets Pty Ltd (The La Wilson Property A/C) 9,193,503 0.50%
Retzos Executive Pty Ltd (Retzos Executive S/Fund A/C) 8,500,000 0.50%
National Nominees Limited 8,021,759 0.50%
R & J Smith Shareholding Pty Ltd (R & J Smith Shareholding A/C) 7,530,531 0.40%
Australian Executor Trustees Limited (Ips Super A/C) 7,514,401 0.40%
Xue Investments Pty Limited (Xue Family A/C) 6,025,589 0.30%

Profile

since

Note